It has been recently proposed that the two "emerging" hallmarks of cancer, namely altered glucose metabolism and immune evasion, may in fact be fundamentally linked The implications of this hypothesis are investigate using an agent-based model, leading to a prediction that relative CSC to non-CSC ratio will vary with the strength of the host immune response, with the highest occurring at an intermediate state of immune 2 activation. A discussion of possible therapeutic approaches concludes the paper, suggesting that a chemotherapeutic regimen consisting of regular pulsed doses, i.e., metronomic chemotherapy, would yield the best clinical outcome by allowing CTLs to most effectively reach and eliminate CSCs.
activation. A discussion of possible therapeutic approaches concludes the paper, suggesting that a chemotherapeutic regimen consisting of regular pulsed doses, i.e., metronomic chemotherapy, would yield the best clinical outcome by allowing CTLs to most effectively reach and eliminate CSCs.
Introduction
The immune system is generally very effective in preventing budding tumors from progressing to a fully malignant disease (2) (3) (4) . However, as the cytotoxic cells of the immune system attempt to eliminate the tumor, they effectively select for nonimmunogenic clones, thus delaying but not arresting tumor progression, a process that has become known as tumor immunoediting (2; 5-7). Moreover, tumors that have been 'edited' in this fashion are typically more aggressive than their 'unedited' counterparts due to selection for more immunoresistant clones; a property first demonstrated by Shankaran and colleagues (8) .
It has been recently proposed that the process of immunoediting may additionally be driven by competition for resources between cancer and immune cells in the tumor microenvironment (1) . Specifically, the following microenvironmentally-based immunoediting scenario has been proposed: 1) As the tumor increases in size while not yet recognized by the cytotoxic cells of the immune system, it begins to outgrow its blood supply, causing the formation of oxygen-deprived regions in the tumor interior.
2) Intra-tumoral hypoxia causes the affected tumor cells to turn to glycolysis as a primary mode of glucose metabolism; an event known to be accompanied by an up to 30-fold up-regulation of the activity of glucose transporters (9).
3) Once activated, the CTLs first attack the topologically accessible outer rim of the tumor, what we term the 'protective shield', thus effectively exposing the tumor's 'glycolytic core'.
4) The exposed glycolytic tumor cells, which have been forced to up-regulate their glucose transporters, now actively compete with CTLs for glucose.
5)
In a nutrient-deprived state, CTLs are less able to perform their tumoricidal function, allowing the tumor as a whole to evade immune attack.
In this way, the process of immune evasion may be the result of a competition for resources in the tumor microenvironment.
Here, this construct is expanded to incorporate cancer stem cells (CSCs). Because CSCs comprise a relatively small fraction of the tumor population on account of their high probability of asymmetric division (producing one CSC and one non-stem cell) (10), they will tend to surround themselves with non-stem progeny, which then could follow the aforementioned immunoediting scenario . The non-CSCs will then protect CSCs from cytotoxic lymphocytes both by creating a physical barrier and through outcompeting CTLs for essential nutrients. These considerations are summarized in Figure 1 . Figure 1 . Schematic representation of the proposed immunoediting construct, which incorporates CSCs using aerobic and particularly glycolytic non-CSCs as a protective 'shield' from cytotoxic lymphocytes.
The proposed theoretical framework allows making predictions about CSC content in different tumors with regards to the immune response, which can be of vital importance, as CSCs, the driving cells in cancer progression, are believed to be more resistant to cytotoxic therapy than non-CSCs (11) (12) (13) (14) . In this case, if CSCs produced too few non-CSCs, protection from the immune system could be insufficient. If CSCs produced too many non-CSCs, then the progeny may themselves become limiting to CSC expansion, offsetting their benefit as an immune shield. Successful tumors might therefore be predicted to be those that have some optimal intermediate CSC-to-progeny proportion. In addition, this proportion may well be different for different initial states of the immune system.
To test these ideas, an agent-based model is implemented, incorporating the foregoing and other basic assumptions about the properties of CSCs, non-CSCs, immune cells and their interactions with each other and with the resources in the tumor microenvironment. We use this model to illustrate the proposed immunoediting construct and in particular, to evaluate the proposition that varying proportions of CSCs to nonCSCs might be expected in successful tumors under different immune conditions.
Model description
Here we build upon a previously introduced agent-based model (15) , adapting it to describe the interactions between cancer stem cells (CSCs), aerobic and glycolytic nonstem cancer cells (non-CSCs), and cytotoxic lymphocytes (CTLs) with each other and their microenvironment. The model is implemented in Netlogo 5.0.2, a freely available agent-based modeling platform (16) . Space in this simulation is represented by a 2-dimensional 51x51 lattice. Each patch (square) in the lattice represents a discrete microenvironment, the properties of which are detailed below, for a total of 2601 microenvironments. Cells occupy coordinates in continuous space, and more than one cell can occupy a single microenvironment. Time is modeled in discrete steps.
Parameter estimation
Parameter estimation is a common challenge in analyzing results from computational models. One particular difficulty lies in the fact that the estimates obtained in an experimental setting are typically a result of a multitude of complex interconnected processes, which cannot always be separated out for the purposes of a conceptual proof-of-concept model. We address this issue in the following ways. A number of parameters, such as cell growth rates, were previously estimated in a model introduced and analyzed in (15) , where the authors utilize an agent-based model to evaluate the impacts of disregulated glucose metabolism on overall tumor dynamics. We modify their proposed model, shifting the focus of our investigation away from evolution of cell motility and instead introducing immune cells and cancer stem cells as active competitors for glucose in the tumor microenvironment.
Nevertheless, parameters that pertain to tumor growth rates and glucose consumption rates can be well translated into our model.
For a number of other parameters, while it may not always be possible to obtain exact values for reasons outlined above, we attempt to make estimations based on the parameters' relative values to each other. That is, while we may not be able to estimate exact rates of glucose consumption by cytotoxic immune cells, for instance, we can nevertheless support the notion that highly proliferative CTLs, just as glycolytic tumor cells, consume more energy than do aerobic tumor cells (17) .
Morover, Buttgereit and Brand (18) reported that in a model of concanavlin Astimulated thymocytes, where it is possible to account for over 80% of ATP consumption, protein synthesis was the most sensitive to limitations in glucose supply, followed by DNA and RNA synthesis and then by ion transport across plasma membrane. Motility also has been reported to incur significant ATP costs for immune cells due to energy requirements for cytoskeleton rearrangement during movement (19) . Therefore, while we may not be able to obtain the exact values for the costs of motility and cytotoxicity for CTLs, we can nevertheless assert that these costs exist, and are incorporated as such. Moreover, since we do not have exact estimates for these costs, they are taken to be a unit of energy each, an assumption which can be relaxed or modified pending data availability.
The specific assumptions for each of the cell types and for the microenvironments are as follows:
Properties of aerobic non-CSCs: Aerobic non-CSCs require glucose and oxygen for survival and glucose for proliferation, although they have lower glucose requirements than glycolytic non-CSCs. They die at some natural rate, as well as after a certain number of divisions, and can also be killed by CTLs. They can 'switch' to the glycolytic mode of metabolism under conditions of oxygen deprivation. When a cell divides, the daughter cell moves to a random neighboring patch.
Properties of glycolytic non-CSCs: Glycolytic non-CSCs do not require oxygen, but require glucose for survival and proliferation; they consume more glucose to support these processes than aerobic non-CSCs. They die at some natural rate, as well as after a certain number of divisions, and can also be killed by CTLs. They can 'switch' to the aerobic mode of glucose metabolism under conditions of sufficient oxygen availability.
When a cell divides, the daughter cell moves to a random neighboring patch.
Properties of cancer stem cells:
Depending on oxygen availability, CSCs consume oxygen and glucose like aerobic or glycolytic cells. Each CSC division occurs symmetrically with a certain probability. If a CSC divides asymmetrically, the daughter non-CSC cell is initialized to be aerobic, a state which may change. Each cell can die due to nutrient deprivation or be killed by CTLs. CSCs can divide an unlimited number of times. When a CSC divides, the daughter cell moves to a random neighboring patch. 2) Each cell consumes glucose, subtracting differentially from the glucose available on the patch and adding a number of energy units to the cell's storage, according to its 'metabolic phenotype', i.e., aerobic or glycolytic; glycolytic cells consume glucose, while aerobic cells consume both glucose and oxygen.
Properties of cytotoxic immune cells:
3) Cytotoxic lymphocytes move randomly throughout the microenvironment, killing the tumor cells that they encounter; both motility and the process of cell killing have a cost of a unit of energy each; CTLs die if their energy stores are depleted and cannot be replenished. 4) Each cell reproduces with a certain fixed probability, given adequate resources in the microenvironment; the daughter cell moves to a random neighboring patch; if the cell is a CSC, it divides symmetrically or asymmetrically with a certain probability; in case of asymmetric division, the daughter cell is initialized as aerobic non-CSC. Since the purpose of the proposed model is to offer a 'proof-of-concept' as to whether tumor composition can indeed be affected by the initial state of the immune system of the host, parameter values were chosen as relative to each other rather than matching them to fit a particular data set.
It is hypothesized that in successfully formed tumors, the relative proportion of non-CSCs will increase proportionally to the strength of the immune response because CSCs will require the shielding effect of non-CSCs to protect them from CTLs.
Specifically, an increase in the proportion of glycolytic non-CSCs is predicted, since they are capable of competing most effectively with CTLs for glucose in the tumor microenvironment.
Results
The numerical experiments were designed in such a way as to enable evaluation of tumor composition at each time point with respect to the state of the immune system. The initial state of the immune response was modeled with parameter i0=0, 10, 20, 30, 35, 40. For each i0, 20 simulations were run for 1000 time steps, and the mean number of CSCs, aerobic and glycolytic non-CSCs were reported; only the data for tumors that had at least one CSC at t=1000 were collected. The data is represented in two types of plots: the change over time of tumor composition for each respective i0 and the final ratio of CSC to non-CSC at t=1000 for each i0.
Proportion of glycolytic cells increases with the strength of the immune response
Our simulations show that indeed, stronger immune response predicts larger overall proportion of glycolytic non-CSCs in the tumor (see Figure 2) , which within the proposed theoretical framework is explained by the increased 'need' of CSCs to protect themselves from the immune system. However, the largest proportion of CSCs in the tumor at t=1000 was observed at the intermediate values of i0 (see Figure 3) . Therefore, since they are not 'sacrificed' to the immune system, aerobic non-CSCs outcompete CSCs.
At high values of i0, the tumor is not able to grow to a large enough size to create sufficiently hypoxic regions that would allow for the appearance of large clusters of glycolytic non-CSCs that would present sufficient competition to cytotoxic lymphocytes.
In this case, the non-CSC 'shield' would not be strong enough to contain CTLs. . Change in tumor composition of CSCs (green) to glycolytic nCSCs (red) to aerobic nCSCs (blue) over time for varying initial states of the host immune system, represented by parameter i0. The probability of recognition of CSC by a CTL is 50% lower than probability of recognition of nCSC. Threshold of sensitivity to oxygen for all cells is set to ω=5. Figure 5 . Proportion of CSCs and nCSCs at t=1000 for all varying initial states of the host immune system, represented by parameter i0. The probability of recognition of CSC by a CTL is 50% lower than probability of recognition of nCSC. Threshold of sensitivity to oxygen for all cells is set to ω=5.
Variability in sensitivity to oxygen does not affect final tumor composition regardless of the state of the immune system
In the previous set of in silico experiments, it was assumed that all cells have a fixed threshold of sensitivity to oxygen and therefore revert to either aerobic or glycolytic mode of glucose metabolism based on a criterion that is uniform for all cells. It is however possible that if there were heterogeneity among cells based on this metric, one could observe selection for cells that are either more or less sensitive to oxygen concentrations in their microenvironment depending on the state of the immune response.
That is, one could observe selection towards lower oxygen sensitivity thresholds (described by the value of parameter ω) under the conditions of increased selective pressure from the immune system.
In order to evaluate this hypothesis, the above-described protocol was modified to introduce mutations in parameter ω every time a tumor cell divides. The changes in the mean value of ω were recorded for all three cell types for all i0. The overall tumor composition changed in the same way with respect to different i0 as it did for the case of constant ω (Figure 6 ), and the largest proportion of CSCs was also observed for the intermediate values of i0 ( Figure 7) . The mean value ω for glycolytic cancer cells did oscillate increasingly with stronger immune response (Figure 8 ). However, a 2-tailed type 1 t-test did not reveal any statistically significant changes either in overall tumor composition or in the values of ω at t=1000 for either of the three tumor cell types (Figure 9 ), These results suggest that it is not oxygen availability but competition for glucose, both within the tumor and between cancer and immune cells, that is the driving force behind the observed dynamics of immune evasion. Figure 6 . Change in tumor composition of CSCs (green) to glycolytic nCSCs (red) to aerobic nCSCs (blue) over time for varying initial states of the host immune system, represented by parameter i0. As one can see, the proportion of glycolytic nCSCs tends to increase with i0 as CSCs require increased protection from CTLs. Threshold of sensitivity to oxygen for all cells is initiated at ω=5 but is allowed to mutate with each cell division for each cell. . Change in the mutating threshold of sensitivity to oxygen (parameter ω) over time for varying initial states of the host immune system, represented by parameter i0. As one can see, while ω oscillates increasingly for larger i0, the mean of ω remains largely the same for all three cell types. Figure 9 . Mean value of the threshold of sensitivity to oxygen (parameter ω) at t=1000 for varying initial states of the host immune system, represented by parameter i0, compared to fixed value of ω=5 for the first set of simulations. While there are slight changes in ω for all three cell types, none of them were statistically significant as evaluated by a 2-tailed type 1 t-test, suggesting that it is not oxygen availability.
Discussion
Here a theoretical framework is proposed, where CSCs can escape recognition by cytotoxic lymphocytes by creating a 'shield' of differentiated non-CSCs around them.
These shielding cells not only provide a physical barrier to the immune cells but also create a local nutrient flux, thereby starving CTLs out of functionality. Specifically, we proposed that if a CSC divided asymmetrically before it was recognized by the CTLs, The proportion of glycolytic non-CSCs increased dramatically with increased immune response (Figure 2 ), supporting the initial hypothesis. Moreover, the proportion of CSCs was largest not for the strongest or weakest states of the immune response but for intermediate ones (Figure 3) , supposedly because in this case the tumor can grow large enough to create hypoxic regions but it small enough that the non-stem progeny do not outcompete CSCs.
Next, we hypothesized that if each cell had an individual threshold of sensitivity to oxygen, which would determine oxygen-based threshold for a "glycolytic switch", then over time selection towards cells with lower threshold could be observed. However, while the threshold of sensitivity to oxygen ω did change slightly over time, the changes both in tumor composition, as well as in the mean values of ω for all three cell types was not statistically significant (Figures 8 and 9 ), suggesting that oxygen availability is less of a crucial determinant of the outcome of tumor progression compared to glucose. It is of course not possible to claim that competition for common nutrients is the sole mechanism whereby CSCs can avoid recognition by the immune system. Instead, we propose that competition for resources can provide an additional mechanism whereby 
Game theory and cancer
It has become increasingly recognized and accepted that tumor dynamics is governed largely by the process of Darwinian selection, where tumor cells experience and respond to various selective pressures, such as competition for resources with each other and somatic cells, interaction with predators (the immune system), migration (metastases), all within the 'ecosystem' of the human body (24) (25) (26) (27) (28) (29) (30) (31) . One of the well-developed analytical approaches to understanding evolving populations is evolutionary game theory, which has already been partially applied to cancer (33) (34) (35) (36) (37) (38) (39) . The main premise of this approach is the assumption that individuals, such as cells, operate for immediate optimization of their payoff, which in the context of evolutionary game theory is fitness, i.e., survival and the number of progeny. Individuals may use different strategies to achieve this goal, and understanding of these strategies and their immediate consequences can provide understanding about why a system is evolving in a particular direction.
In the context of the proposed model, we assume that it is CSCs that want to maximize their fitness and produce a maximal number of other CSCs. They can achieve this goal using two strategies: symmetric or asymmetric division, yielding either two CSCs or one CSC and one non-CSC, respectively. Symmetric division allows yields more CSCs immediately. Asymmetric division may allow for survival of the progeny in the long term.
From this point of view, in the absence of the immune response, or if it did not affect the growth dynamics CSCs, one would expect eventual CSC enrichment, as is predicted by a number of previously published theoretical models (40, 41) , since it is symmetric division that would allow CSCs to maximize their fitness. However, in the presence of the immune response, the 'optimal strategy' becomes mixed, since in order to maximize their fitness CSCs now have to divide asymmetrically to protect themselves from the immune cells, and the position of the 'equilibrium strategy', i.e., the number of times the CSC would need to divide symmetrically or asymmetrically in order to maximize its fitness, would be different depending on the initial state of the immune response.
Perhaps, manipulating the tumor microenvironment in such a way as to select for the increased asymmetric CSC division could be a potentially fruitful strategy to make the tumor more vulnerable to anti-cancer therapies.
Therapeutic implications
Cancer stem cells are hypothesized to be the driving force behind unrestrained tumor growth, as they are also resistant to a number of cytotoxic therapies (13; 42-45) . One possible way to circumvent this problem could involve taking advantage of the immune cells, which might be able to eliminate CSCs, even if less efficiently compared to nonCSCs (23, (46) (47) (48) . However, if the proposed construct is correct, CTLs are unable to do so because of the 'shield' of differentiated tumor cells that restricts their access to CSCs. Therefore, the optimal therapeutic strategy in this case would be not the one to cause the most extensive cell mortality but the one that will facilitate the access of cytotoxic immune cells to CSCs.
Two main considerations CSCs and CTLs need to be taken into account. Firstly, both theoretical considerations, outlined here, and experimental evidence suggest that CSCs are to be primarily found in the hypoxic areas of the tumor (49, 50) , where they are the most 'protected' from the immune cells. Secondly, extensive cytotoxic therapies are highly damaging to the immune cells themselves (51) , and consequently gained access the tumor core and the CSCs would be ineffective if there remain no immune cells that could then attack the CSCs.
The three major approaches that can be taken in chemotherapy administration are MTD (maximum tolerated dose), metronomic, and continuous therapy, which is a particular case of the metronomic therapy.
As the name suggests, MTD involves administering the highest possible dose of cytotoxic drugs that a patient can tolerate, with the intention of damaging a maximal number of cells and expectation that normal tissues would be able to recover better than cancerous ones. The major drawback of MTD from the point of view of the considerations, outlined above, is the damage that it causes to the immune cells (51) .
Therefore, even if this could be a good way to reach the CSCs, it is very likely that the time it would take for the anti-tumor immune cells to recover would be greater than the time it would take for the CSCs to form another 'shield'. Noticeably, these predictions should hold as long as CSCs can be recognized by CTLs.
Continuous therapy involves administering very low doses of chemotherapy on a daily basis, ensuring constant presence of the cytotoxic drug in the patient's body. While this approach is much less toxic to the patient, it still has a problem of giving no time for the anti-tumor immune cells to recover, since they would be constantly eliminated by continuous inflow of cytotoxic chemical agents.
Metronomic therapy provides an intermediate case between MTD and continuous therapy, and involves administering lower doses of chemotherapy at more frequent intervals, but not on a daily basis. This approach could ensure continual 'peeling off' of the outer layers of the tumor, which protect the CSCs, thus giving anti-tumor immune cells access to the tumor core, while allowing sufficient time for CTLs to recover from the damaging effects of the therapy and attack the CSCs, thereby giving the best chance for more successful long-term tumor elimination.
Conclusions
Limited success of some therapies may be rooted not in the lack of effectiveness of the cytotoxic drugs themselves but in the lack of understanding of tumor topology. If the differentiated non-CSC cells do indeed provide a barrier to both chemotherapeutic agents and the body's natural defenses, then the problem of halting cancer progression might be overcome with appropriate mode of therapy administration. Specifically, if therapyresistant CSCs do shield themselves from anti-tumor immune cells by 'hiding' in the tumor's hypoxic regions, then slowly exposing these areas using moderate but relatively frequently administered levels of chemotherapy might give a better chance for cytotoxic lymphocytes to eliminate the tumor.
